Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05686083 · ClinicalTrials.gov registry record · NA
Pharmacokinetics of Two Fatty Acid Ketone Esters
A NA study of Pharmacokinetics, sponsored by BHB Therapeutics, Ireland.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05686083 is a NA study of Pharmacokinetics that has completed, run by BHB Therapeutics, Ireland. The registered enrollment target is 12 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05686083, a NA study of Pharmacokinetics, has completed, sponsored by BHB Therapeutics, Ireland.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized, cross over pharmacokinetic study of a novel ketone di-ester and C6 ketone di-ester in ready to drink beverage matrices.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT C6 ketone di-ester
- DIETARY_SUPPLEMENT Novel ketone di-ester
Study Locations (1)
Illinois
- Biofortis - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05686083
The ClinicalTrials.gov registry entry for NCT05686083 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (81% lower). The listed sponsor is BHB Therapeutics, Ireland, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which C6 ketone di-ester is the first listed.
NCT05686083 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05686083 about?
NCT05686083 is a clinical study titled "Pharmacokinetics of Two Fatty Acid Ketone Esters". Randomized, cross over pharmacokinetic study of a novel ketone di-ester and C6 ketone di-ester in ready to drink beverage matrices.
What is the current status of trial NCT05686083?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2023-01-30. Estimated completion is 2023-03-31.
What conditions does trial NCT05686083 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT05686083?
The interventions under investigation include: C6 ketone di-ester (DIETARY_SUPPLEMENT), Novel ketone di-ester (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05686083?
This trial is sponsored by BHB Therapeutics, Ireland, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05686083 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetic Profile of N-Acetyl Cysteine
COMPLETED · NA
-
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
COMPLETED · NA
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.